Achieving a healthier weight can decrease the risk of complications associated with obesity, such as diabetes, fatty liver disease, sleep apnea, heart disease, depression, joint pain, and certain cancers
These interactions are further complicated by metabolic conditions such as obesity and diabetes, where hormonal resistance (e.g., leptin, insulin) and neurotransmitter dysregulation contribute to altered taste preferences and compulsive eating behaviors
The injectable GLP-1s do have a fairly long half-life, of about four or so weeks
10.3389/fphys.2018.01622 Summary Keywords dipeptidyl peptidase-4, glucagon-like peptide-1, incretin, peptide degradation, therapy, type 2 diabetes Citation Deacon CF (2019) Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
in Vitamins & Hormones , Vol